This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Tyme Technologies Crescita futura

Future criteri di controllo 0/6

Informazioni chiave

n/a

Tasso di crescita degli utili

n/a

Tasso di crescita dell'EPS

Biotechs crescita degli utili	28.4%
Tasso di crescita dei ricavi	n/a
Rendimento futuro del capitale proprio	n/a
Copertura analitica	None
Ultimo aggiornamento	n/a

Aggiornamenti recenti sulla crescita futura

Recent updates

Syros, Tyme Technologies jump more than 20% after hours as shareholders approve merger

Sep 15

Here's Why We're Not Too Worried About Tyme Technologies' (NASDAQ:TYME) Cash Burn Situation

Nov 19

Tyme Technologies: The Market Missed The Bullish Memo

Aug 27

We're Not Very Worried About Tyme Technologies' (NASDAQ:TYME) Cash Burn Rate

Jul 19

Tyme Technologies reports FY results

Jun 10

Tyme Technologies: Recent Sell-Off Provides Opportunity To Buy At A Discount

May 29

Here's Why We're Watching Tyme Technologies' (NASDAQ:TYME) Cash Burn Situation

Mar 26

Have Tyme Technologies, Inc. (NASDAQ:TYME) Insiders Been Selling Their Stock?

Feb 19

Tyme falls after equity offer as quarterly data indicate liquidity pressure

Feb 04

Tyme stock granted U.S. patent claims for using TYME-19 to treat COVID-19 infections

Feb 03

Do Institutions Own Tyme Technologies, Inc. (NASDAQ:TYME) Shares?

Feb 02

Revisiting Tyme Technologies

Dec 17

Have Insiders Sold Tyme Technologies, Inc. (NASDAQ:TYME) Shares Recently?

Dec 16

Is Tyme Technologies (NASDAQ:TYME) In A Good Position To Invest In Growth?

Dec 09

Tyme Technologies names new finance chief

Nov 30

In questa sezione di solito presentiamo le proiezioni di crescita dei ricavi e degli utili basate sulle stime di consenso degli analisti professionisti per aiutare gli investitori a capire la capacità della società di generare profitti. Tuttavia, poiché Tyme Technologies non ha fornito dati sufficienti sul passato e non ha previsioni degli analisti, i suoi utili futuri non possono essere calcolati in modo affidabile estrapolando i dati passati o utilizzando le previsioni degli analisti.

Si tratta di una situazione piuttosto rara, dato che il 97% delle società coperte da SimplyWall St dispone di dati finanziari passati.

Previsioni di crescita degli utili e dei ricavi

NasdaqCM:TYME - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
6/30/2022	N/A	-24	-20	-20	N/A
3/31/2022	N/A	-24	-21	-21	N/A
12/31/2021	N/A	-24	-19	-19	N/A
9/30/2021	N/A	-25	-21	-21	N/A
6/30/2021	N/A	-26	-23	-23	N/A
3/31/2021	N/A	-29	-24	-24	N/A
12/31/2020	N/A	-28	-24	-24	N/A
9/30/2020	N/A	-28	-23	-23	N/A
6/30/2020	N/A	-28	-20	-20	N/A
3/31/2020	N/A	-22	-20	-20	N/A
12/31/2019	N/A	-27	-18	-18	N/A
9/30/2019	N/A	-29	-19	-19	N/A
6/30/2019	N/A	-29	-19	-19	N/A
3/31/2019	N/A	-33	-20	-20	N/A
12/31/2018	N/A	-27	-20	-20	N/A
9/30/2018	N/A	-25	-17	-17	N/A
6/30/2018	N/A	-23	-15	-15	N/A
3/31/2018	N/A	-19	-12	-12	N/A
12/31/2017	N/A	-17	-10	-10	N/A
9/30/2017	N/A	-14	-9	-9	N/A
6/30/2017	N/A	-12	-7	-7	N/A
3/31/2017	N/A	-15	-6	-6	N/A
12/31/2016	N/A	-17	-6	-6	N/A
6/30/2016	N/A	-13	-6	-6	N/A
3/31/2016	N/A	-11	N/A	-5	N/A
12/31/2015	N/A	-12	N/A	-7	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Insufficient data to determine if TYME's forecast earnings growth is above the savings rate (1.9%).

Guadagni vs Mercato: Insufficient data to determine if TYME's earnings are forecast to grow faster than the US market

Guadagni ad alta crescita: Insufficient data to determine if TYME's earnings are expected to grow significantly over the next 3 years.

Ricavi vs Mercato: Insufficient data to determine if TYME's revenue is forecast to grow faster than the US market.

Ricavi ad alta crescita: Insufficient data to determine if TYME's revenue is forecast to grow faster than 20% per year.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Insufficient data to determine if TYME's Return on Equity is forecast to be high in 3 years time

This company has been acquired

Tyme Technologies Crescita futura

Future criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Price target increased to US$9.44

Recent updates

Tyme Technologies, Inc.(NasdaqCM:TYME) dropped from NASDAQ Composite Index

Tyme Technologies, Inc. Announces Board Changes

Syros, Tyme Technologies jump more than 20% after hours as shareholders approve merger

We Think Tyme Technologies (NASDAQ:TYME) Can Afford To Drive Business Growth

Tyme Technologies, Inc. (NasdaqCM:TYME) entered into a definitive merger agreement to acquire Tyme Technologies, Inc. (NasdaqGS:SYRS) from Adage Capital Partners, L.P., Samsara Biocapital, L.P., Jalaa Equities, L.P., Flagship Pioneering Fund VII, CVI Investments, Inc. and others for $67.6 million.

TYME stock surges on merger agreement and Syros Pharmaceuticals

Tyme Technologies Receives Extension to Regain Compliance with the Nasdaq Continued Listing Standards

Tyme Technologies: Net-Net Biopharma Exploring Strategic Alternatives

Co-Founder & Director notifies of intention to sell stock

Co-Founder & Director notifies of intention to sell stock

Insufficient new directors

Insufficient new directors

We Think Tyme Technologies (NASDAQ:TYME) Can Afford To Drive Business Growth

Co-Founder notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

Tyme Technologies, Inc. to Report Q3, 2022 Results on Feb 11, 2022

Tyme Technologies, Inc. Provides Update on Precision Promise Trial in Metastatic Pancreatic Cancer

Tyme Technologies, Inc. Announces Additional Encouraging Preclinical Data on the Effect of TYME-19 in SARS CoV-2 Infections

Tyme Technologies Offers Incredible Risk-Reward

Here's Why We're Not Too Worried About Tyme Technologies' (NASDAQ:TYME) Cash Burn Situation

Co-Founder notifies of intention to sell stock

TYME Technologies, Inc. Announces First Patient Dosed in Phase II OASIS Trial Evaluating the Potential Benefits of Oral SM-88 for Patients with Metastatic HR+/HER2- Breast Cancer After Treatment with a CDK4/6 Inhibitor

Independent Director recently bought US$52k worth of stock

Tyme Technologies: The Market Missed The Bullish Memo

Co-Founder notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

We're Not Very Worried About Tyme Technologies' (NASDAQ:TYME) Cash Burn Rate

Tyme Technologies, Inc.(NasdaqCM:TYME) dropped from Russell 3000 Growth Index

Tyme Technologies reports FY results

Tyme Technologies: Recent Sell-Off Provides Opportunity To Buy At A Discount

Co-Founder notifies of intention to sell stock

Price target increased to US$9.44

Chief Medical Officer has left the company

Here's Why We're Watching Tyme Technologies' (NASDAQ:TYME) Cash Burn Situation

Insider recently sold US$55k worth of stock

Have Tyme Technologies, Inc. (NASDAQ:TYME) Insiders Been Selling Their Stock?

Insider recently sold US$55k worth of stock

Tyme falls after equity offer as quarterly data indicate liquidity pressure

New 90-day high: US$3.53

Tyme stock granted U.S. patent claims for using TYME-19 to treat COVID-19 infections

Do Institutions Own Tyme Technologies, Inc. (NASDAQ:TYME) Shares?

Co-Founder notifies of intention to sell stock

New 90-day high: US$1.34

Revisiting Tyme Technologies

Co-Founder recently sold US$613k worth of stock

Co-Founder notifies of intention to sell stock

Have Insiders Sold Tyme Technologies, Inc. (NASDAQ:TYME) Shares Recently?

Is Tyme Technologies (NASDAQ:TYME) In A Good Position To Invest In Growth?

Tyme Technologies, Inc. Announces Executive Changes

New 90-day high: US$1.05

Tyme Technologies names new finance chief

Tyme Technologies, Inc. Announces Resignation of Ben R. Taylor as Chief Financial Officer

New 90-day low: US$0.92

Co-Founder notifies of intention to sell stock

Tyme Technologies, Inc. Announces Executive Changes

New 90-day low - US$0.98

New 90-day low - US$1.17

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita